This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Spyt, T. Articles by Rumley, A. Search for Related Content PubMed Articles by Spyt, T. Articles by Rumley, A. Social Bookmarking                         What's this?

The effects of desmopressin acetate (DDAVP) on haemostasis and blood loss in routine coronary artery bypass surgery: a randomized, double-blind trial I

Department of Cardiac Surgery, Western Infirmary

NA Weerasena

Department of Cardiac Surgery, Western Infirmary

WH Bain

Department of Cardiac Surgery, Western Infirmary

Gdo Lowe

University Department of Medicine, Royal Infirmary, Glasgow

A. Rumley

University Department of Medicine, Royal Infirmary, Glasgow

A previous study has found that desmopressin (DDAVP), which releases factor VIII/von Willebrand factor from vascular endothelium, significantly reduces blood loss after complicated cardiac bypass surgery. To determine whether or not desmopressin reduces blood loss or transfusion requirements after routine coronary artery bypass surgery, we randomized 100 patients to receive, double-blind, either desmopressin (0.3 µg/kg over 30 minutes intravenously) or placebo at the end of cardiopulmonary bypass. The two groups were similar in age, sex, prior aspirin use and number of coronary grafts. Following desmopressin infusion, factor VIII coagulant activity was higher than in the placebo group (117 ± 31 versus 95 ± 48 iu/dl, p < 0.05) as was von Willebrand factor antigen (141 ± 53 versus 114 ± 40 iu/dl, p < 0.01). No significant changes in fibrinolysis (fibrin plate lysis area) were observed in either group. Despite this haemostatic effect, patients treated with desmopressin had similar postoperative blood loss to the placebo group (1029 ± 523 versus 976 ± 441 ml) and similar blood transfusion requirements (67.5 units in 33 patients versus 63.5 units in 35 patients). There were no significant differences between groups in the incidence of complications, including postoperative hyponatraemia. We conclude that desmopressin is not useful in reducing blood loss after routine, uncomplicated coronary artery bypass surgery.

Perfusion, Vol. 5, No. 1 suppl, 57-61 (1990)
DOI: 10.1177/026765919000500109


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				E. W. Salzman, M. J. Weinstein, D. Reilly, and J. A. Ware Adventures in Hemostasis: Desmopressin in Cardiac Surgery Arch Surg, February 1, 1993; 128(2): 212 - 217. [Abstract] [PDF]